Table 4 Resistance profiles of antiviral therapies
Resistance profiles | |||||||
|---|---|---|---|---|---|---|---|
Year | ADV | LDT | LAM | ETV | TDF | LDT + ADV | LDT + TDF |
1 | 0 % | 3 % | 9 % | 0 % | 0 % | 3 % | 3 % |
2 | 2 % | 15 % | 22 % | 1 % | 0 % | 15 % | 15 % |
3 | 5 % | 15 % | 22 % | 3 % | 0 % | 15 % | 15 % |
4 | 8 % | 15 % | 22 % | 3 % | 0 % | 15 % | 15 % |
5 | 8 % | 15 % | 22 % | 3 % | 0 % | 15 % | 15 % |
GLOBE trial (Liaw et al. 2009) | Zhang et al. (2015) | Piratvisuth et al. (2013) | Conservative assumption of resistance of same as LDT | Conservative assumption of resistance of same as LDT | |||